Holistic Treatment of Patients with HRpos HER2neg MBC and Comorbidities

CME

Treating the Whole Patient: Understanding Needs of Patients With HR-Positive/HER2-Negative MBC and Comorbidities

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: March 07, 2025

Expiration: September 06, 2025

Activity

Progress
1 2
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Breast cancer. Version 1.2025 nccn.org. Accessed March 4, 2025.
  2. Rugo HS, Finn RS, Dieras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719-729.
  3. Slamon DJ, Dieras V, Rugo HS, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42:994-1000.
  4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942-950.
  5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541-1547.
  6. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res. 2022;28:851-859.
  7. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904-915.
  8. Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35:718-727.
  9. Abemaciclib [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2025.
  10. Palbociclib [prescribing information]. New York, NY: Pfizer Inc; 2024.
  11. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.
  12. Lu YS, Mahidin E, Azim H, et al. Final results of RIGHT Choice: Ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol. 2024;42:2812-2821.
  13. Loibl S, Thill M, Roy J, et al. Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. Presented at: San Antonio Breast Cancer Symposium; 2024. Abstr LB1-03.
  14. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-529.
  15. Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391:1584-1596.
  16. Inavolisib [prescribing information]. South San Francisco, CA: Genentech USA, Inc; 2024.
  17. Ward M, Harnett J, Bell TJ, et al. Risk factors of QTc prolongation in women with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer: A retrospective analysis of health care claims data. Clin Ther. 2019;41:494-504 e491.
  18. Tagliaferri B, Mollica L, Palumbo R, et al. Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR(+)/HER2(-) breast cancer treated with CDK4/6 inhibitors and endocrine therapy. Drugs Context. 2023;12.